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SOLUTE PARTITIONING IN ELASTIN-LIKE POLYPEPTIDES:  A 
FOUNDATION FOR DRUG DELIVERY APPLICATIONS 
 
ERIC HELM 
ABSTRACT 
Elastin-like polypeptides (ELPs) are a class of biopolymers with the potential to 
function as a novel drug delivery platform.  These protein based polymers are composed 
of the repeating pentapeptide sequence (G𝛼GβP)n where n is the number of pentapeptide 
repeats while 𝛼 and β are guest amino acid residues.  ELP constructs have been designed 
to respond to various external stimuli including temperature, pH, and ionic strength 
where their response to these stimuli results in the separation of the ELP from solution.  
This phase separation results in a two-phase system consisting of a protein poor 
supernatant phase and a protein rich coacervate phase. 
Under certain conditions select ELP constructs are able to self assemble into 
micellar structures of nanometer scale when raised above their transition temperature.  
The micellar architecture consists of an inner hydrophobic core, with a composition like 
that of the protein rich coacervate phase, surrounded by hydrophilic head groups.  For the 
use of ELP micelles as a drug delivery platform these particles should possess the ability 
to encapsulate solute molecules.  In this study, solute solubility within the micelle core 
was investigated by measuring the partition coefficients of several solutes in five 
different ELP two-phase systems, then all data was fit to a linear free energy relationship 
(LFER) model to provide insight into the dominate interactions governing solute 
 v 
 
partitioning in ELP systems.  From the LFER it is shown that the cavity formation 
energy, solute size, and the solvents hydrogen bond acidity are important parameters 
governing solute partitioning in the ELP solvents investigated.  Additionally, the partition 
coefficients provide a measurement of ELP phase hydrophobicity from which the 
development of future ELP constructs is possible. 
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CHAPTER I 
INTRODUCTION 
 
1.1  Elastin-like Polypeptides 
Elastin-like polypeptides (ELP) are a class of biopolymers whose amino acid 
composition and sequence mimics that of mammalian elastin.  Elastin is found 
throughout the animal kingdom typically making up the predominant fraction of 
extracellular matrix in tissues such as arterial blood vessels, lung parenchyma, elastic 
ligaments, ear cartilage, and skin. [1]   Its function in these tissues is to provide an elastic 
characteristic, giving them the ability to expand and contract without mechanical failure.  
In fact, during the average human life span the heart will beat more than 2.5 billion times.  
During this process the aorta elastin transitions through billions of cycles of extension 
and recoil without mechanical failure, showing the remarkable properties of elastin as a 
biomaterial. [1]  Naturally occurring elastin contains a repeat of the pentapeptide 
sequence GVGVP.  To expand upon this composition, the ELP class of biopolymers is 
built from the generic pentapeptide sequence (G𝛼GβP)n, where n is the number of 
pentapeptide repeats, and 𝛼 and β are amino acid guest residues.  Substitution of different 
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amino acids into the 𝛼 and β positions as well as altering the number of pentapeptide 
repeats provides a large library of ELP compositions for study.  It has been discovered, in 
order to maintain phase transition behavior and elastic characteristics of the ELP 
construct, the guest reside 𝛼 can be replaced with any amino acid except for proline while 
β can be replaced with any amino acid. [2] 
 Current production of elastin-like polypeptides is performed using an Escherichia 
Coli (E. coli) bacterial host.  Several types of plasmid construction techniques capable of 
ELP production have been presented in the literature. [3, 4, 5]  One plasmid construction 
technique commonly used to build the appropriate plasmid is called recursive directional 
ligation (RDL). [3, 6]  This technique begins with the design of an E. coli expression 
vector compatible with the ELP gene.  Once the appropriate cut sites are in place short 
oligonucleotide segments encoding the amino acid sequence (G𝛼GβP) are inserted.  This 
process is repeated until the desired ELP sequence has been inserted into the vector, then 
the final vector is transformed into an E. coli host for protein expression.  Using genetic 
engineering allows the production of research quantities of ELP and precise control over 
ELP chain length and amino acid sequence, characteristics that give ELPs their 
functionality. 
 
1.1.1  ELP transition temperature 
One interesting feature of elastin-like polypeptides is their display of lower 
critical solution temperature (LCST) behavior.  When the temperature of an aqueous 
solution of ELP is raised above its transition temperature, hydrophobic domains within 
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the protein backbone associate causing the protein to aggregate, resulting in a cloudy 
solution.  The temperature at which the solution begins to cloud is known as the solution 
transition temperature (Tt).  When solutions are allowed to sit above their transition 
temperature settling of the protein layer occurs resulting in a two-phase system composed 
of a protein rich lower “coacervate” phase made of 40-50% protein by mass and a protein 
poor upper “supernatant” phase (Figure 1.1). [2] 
 
 
Figure 1.1  ELP solution phase separation behavior modified from reference [2]. 
 
This phase transition is completely reversible.  Upon cooling the solution below its 
transition temperature, the protein dissolves back into solution.  The transition 
temperature is dependent on both solution and ELP molecular characteristics.  
Characteristics, such as ionic concentration, pH, ELP concentration, ELP chain length, 
and amino acid composition, can be adjusted in order to alter the solution transition 
temperature. 
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Inorganic salt influence on ELP transition temperature 
  Inorganic salt concentration has been known to have a strong effect on protein 
solubility.  Research has shown that ionic salts, more often the salt anion, can influence 
the transition temperature of ELPs. [7]  For the kosmotrophic anions; F-, H2PO4
-, S2O3
2-, 
SO4
2-, CO3
2-, and Cl- a linear relationship exists between transition temperature and ion 
concentration where T0 is the solution transition temperature without the addition of salt, 
[M] is the salt concentration in molar units, and c is a constant with units of 
temperature/molarity, Eq. (1.1).   
 Tt = T0 + c[M] (1.1) 
For these anions, their addition to an ELP solution results in a decrease in the transition 
temperature due to polarization of water molecules and a reduction in hydrogen-bonding 
strength between water molecules and hydrophilic regions of the ELP.  Other anions have 
been shown to increase the transition temperature. [7, 8]  In contrast with the 
kosmotrophic anions these anions; SCN-, I-, ClO4
-, Br-, and NO3
- show a nonlinear 
response in ELP transition temperature as a function of anion concentration.  This 
response has been characterized by adding a binding isotherm to Eq. (1.1), Eq. (1.2), 
 Tt = T0 + c[M] +
𝐵𝑚𝑎𝑥𝐾𝐴[𝑀]
1+𝐾𝐴[𝑀]
 (1.2)  
where KA is the apparent equilibrium constant and Bmax (units of temperature) is a 
constant interpreted as the increase in ELP transition temperature in a saturated anion 
solution. 
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Influence of protein concentration and chain length on ELP transition temperature 
 ELP concentration and chain length have a significant influence on the transition 
temperature.  Research performed by Meyer and Chilkoti has shown a linear relationship 
between transition temperature and the logarithm of the protein concentration for dilute 
ELP solutions, where Cc is the critical concentration in molar units, Tt,c is the critical 
 Tt = Tt,c + kcln⁡(
Cc
C
) (1.3) 
 kc =
k
L
 (1.4) 
transition temperature, kc is a constant in units of 
oC, and L is the number of pentapeptide 
repeats, Eq. (1.3). [9]  In this model the critical values of concentration and temperature 
are the concentration and temperature at which the transition temperature reaches a 
minimum and is no longer dependent on ELP chain length.  This model has been further 
advanced by Ghoorchian and Holland during their investigation into a three-armed star 
ELP (trimer). [10]  Fitting their data, for the trimer construct, to Eq. (1.3) resulted in a 
slightly lower critical transition temperature than expected and the critical concentration 
was one order of magnitude higher than expected.  Due to these discrepancies the 
concentration units were changed to polymer coil volume and the critical concentration 
was arbitrarily defined as 1.  Once again the data was fit to Eq. (1.3), but it this case a 
better fit was achieved for the trimer construct resulting in a single Tt,c independent of 
polymer chain length. 
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Influence of amino acid composition on ELP transition temperature 
 To explore the influence of ELP amino acid composition on transition 
temperature, Urry has developed a hydrophobicity scale by varying the ELP amino acid 
composition under common solution conditions (pH 7.5, 0.15 M NaCl, 0.01 M 
phosphate, protein concentration: 40 mg/mL). [2]  Urry synthesized several high 
molecular weight ELP constructs based on the model poly[fv(GVGVP),fx(GXGVP)], 
where fv and fx were mole fractions spanning a range between 0 and 0.5 and the guest 
residue, X, was one of the 20 naturally occurring amino acids.  The data showed a linear 
relationship between mole fraction, fx, and solution transition temperature for every ELP 
composition investigated.  Extrapolation to a common value of fx = 1 was performed to 
determine the influence of that specific amino acid residue on the hydrophobicity of the 
complete ELP construct.  Hydrophobicity was measured by the transition temperature 
where more hydrophobic amino acid residues resulted in a lower Tt.  Using this 
hydrophobicity scale the transition temperature of an experimental ELP can be estimated 
by adding the influence from each guest residue.  For example, according to Urry’s 
hydrophobicity scale (Table 1.1) the ELP construct [(GVGVP)38(GFGVP)2] results in a 
transition temperature of 21oC. 
𝑇𝑡 =
(38)(24℃) + (2)(−30℃)
(38 + 2)
= 21℃ 
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Table 1.1   Selected Values Obtained from Urry’s Hydrophobicity Scale [2] 
Residue Letter Tt (oC) 
Phenylalanine F -30 
Valine V 24 
 
Influence of added hydrophobicity on ELP transition temperature 
Changing the amino acid composition of an ELP construct is not the only method 
of altering the transition temperature by changing ELP hydrophobicity.  Chilkoti et al. 
has demonstrated that covalently bonding a hydrophobic drug molecule to an ELP can 
alter the solution Tt. [11]  In this study, doxorubicin was covalently attached to an ELP 
through an acid-liable linker.  After the synthesis and purification of the ELP-dox 
conjugate, the Chilkoti group noticed the transition temperature of the conjugate was 
10oC lower than that of the pure ELP.  This example shows how changing the 
hydrophobicity of the ELP construct by attachment of a drug molecule can change the 
transition temperature, similar to the behavior observed when changing the amino acid 
composition of the ELP.  By attaching a hydrophobic drug to the ELP, the overall 
molecule has become more hydrophobic resulting in a decrease in the transition 
temperature. 
 
Influence of solution pH on ELP transition temperature 
 When amino acids capable of accepting or donating a proton are incorporated into 
the ELP structure the transition temperature becomes a function of the solutions pH.  
Chilkoti et al. has investigated this behavior by varying the solution pH for two pH 
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responsive ELP constructs, one containing acidic glutamic acid residues and the other 
containing basic histidine residues, then measuring the solutions Tt. [12]  Initially 
Chilkoti’s group determined that for all solution pH values investigated a linear 
relationship was observed between the transition temperature and log protein 
concentration, Eq. (1.3).  Then, using the Henderson-Hasselbach equation Chilkoti’s 
group developed a relationship between transition temperature, solution pH, and ELP 
pKa, Eq. (1.5).  
 Tt = Tpro +
Tdepro−Tpro
1+10(pKa−pH)
 (1.5) 
Equation (1.5) describes the behavior of ELPs containing both acidic and basic amino 
acid residues, where Tdepro and Tpro are the transition temperatures of the fully 
deprotonated and protonated ELP respectively.  For acidic ELP residues Tdepro is greater 
than Tpro therefore, according to Eq. (1.5), the solution transition temperature would 
increase with pH.  For basic ELP residues Tpro is greater than Tdepro resulting in a decrease 
in transition temperature with increasing solution pH.  Identical results were observed by 
our group for glutamic acid and histidine containing ELPs.  Transition temperatures were 
measured as a function of solution pH for a glutamic acid containing ELP, (VEV)12, [13] 
and histidine containing ELP, (V3(VH)3)4 [14]  then, Eq. (1.5) was used to model the data 
(Figure 1.2). 
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Figure 1.2   Transition temperature as a function of solution pH for A) glutamic acid 
containing ELP construct (VEV)12 at a protein concentration of 10 µM in PBS (150 mM 
NaCl, 0.01 M phosphate) with a pKa of 4.8 and B) histidine containing ELP construct 
(V3(VH)3)4 at a protein concentration of 100 µM in PBS with a pKa of 5.3.  Experimental 
data was modeled using Eq. (1.5).  
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The results obtained from our group also follow the treads observed in Urry’s 
hydrophobicity scale.  According to Urry’s scale, ELP constructs become more 
hydrophilic in their charged state, indicated by a higher Tt (Table 1.2).  As shown in 
Figure 1.2, for acidic as well as basic amino acid containing ELPs, the Tt of the ELP 
construct in its charged state is greater than the Tt in its uncharged state. 
 
Table 1.2   Tt Values for Histidine and Glutamic Acid Obtained from Urry’s 
Hydrophobicity Scale [2] 
Residue Abbreviation Letter Tt (oC) 
Histidine His H -10 
Histidine His+ H+ 30 
Glutamic acid Glu E 30 
Glutamate Glu- E- 250 
 
 
1.1.2   Elastin-like polypeptides for use in drug delivery 
The use of elastin-like polypeptides for biological applications has been studied 
for many years.  Research has shown these materials are biocompatible, biodegradable, 
and non-immunogenic. [15]  Since the transition temperature of these materials can be 
finely controlled the main focus of this research has been directed toward investigation 
into applications involving drug delivery.  Potential ELP drug delivery systems are 
constructed by either: directly attaching the drug molecule to the carrier or by 
encapsulation of the drug molecule within a hydrophobic environment. 
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Drug delivery by ELP-drug conjugation 
Chilkoti et al. has demonstrated the direct attachment method of drug delivery by 
covalently bonding the chemotherapeutic drug, doxorubicin, to an ELP for use in cancer 
treatment. [11]  The drug was bound to the ELP through an acid-labile hydrazone linker, 
enabling release of the drug within low pH environments.  The authors state two reasons 
for using an ELP as the drug carrier.  First, when drugs are bound to large 
macromolecules, such as an ELP, tumor permeability and retention within tumor cells 
increases compared to the free drug, an effect known as the enhanced permeability and 
retention effect (EPR).  [16]  Second, if the tumor site is heated above the transition 
temperature of the ELP-doxorubicin conjugate (ELP-dox), accumulation of the drug 
within the tumor can occur resulting in a more efficient drug delivery system. It is 
interesting to note the Chilkoti group has previously shown that fluorescent tagged-ELP 
conjugates will accumulate within tumors that have been heated above the ELP transition 
temperature and this accumulation only occurs when the local temperature is above the 
ELP transition temperature. [17, 18] 
The final results of this study showed a near-equivalent cytotoxicity of the ELP-
dox conjugate and free doxorubicin.  After comparing the cellular distribution of the 
ELP-dox conjugate to free doxorubicin it was shown that the ELP-dox was concentrated 
in the cell cytoplasm, while the free doxorubicin accumulated within the cell nucleus.  
Given this difference in accumulation site, yet an equivalent cytotoxicity of the ELP-dox 
and free doxorubicin, the results suggest a different mechanism of cytotoxicity for the 
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ELP bound drug compared to the free drug.  Similar results were obtained by Moktan et 
al. when investigating a paclitaxel-ELP conjugate where the authors, once again, explain 
this behavior based on a different mechanism of cytotoxicity between the ELP bound and 
free drug. [19] 
 
Drug delivery by ELP-drug encapsulation 
 A study conducted by Wright et al. involved the synthesis and characterization of 
several block ELPs one of which was capable of self assembly into micelles of nanometer 
size. [20]  In dilute concentrations this block polymer formed spherical nanoparticles, at 
25oC under basic conditions (0.1 M NaOH) or PBS (pH 7.4, 0.15 M NaCl, 0.01 M 
phosphate), with an average hydrodynamic diameter of 50-90 nm.  The authors 
investigated the potential of these nanoparticles to encapsulate small molecules using two 
fluorescent dyes, 1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) and Nile Red.  Data 
from this study showed strong association of the dyes with the hydrophobic blocks of the 
ELP indicating encapsulation of the dye within the micelle core.  The authors conclude 
the dyes did not associate with the hydrophilic blocks of the ELP, which supports the 
hypothesis that the hydrophobic blocks were exclusively responsible for the 
encapsulation. 
Similar results were observed by Kim et al. during their investigation into 
disulfide crosslinked, block, ELP micelles loaded with the anti-inflammatory drug 
dipyridamole (DIP). [21]  In this study, 50 nm micelles were loaded with DIP and drug 
release profiles were measured.  The data from the drug release experiments showed an 
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initial burst release over a 3 hour period followed by an extended release over 40 hours.  
When the authors changed the length of the ELP hydrophobic block the resulting 
micelles were of the same diameter, but these micelles were found to release the drug 
more slowly than did the micelles with the shorter block.  The authors suggest this 
difference in release rate be attributed to the more densely packed micelle core formed by 
longer hydrophobic blocks, increasing the interactions between the drug molecule and the 
hydrophobic core.  
 Drug loaded micelles or nanoparticles are not the only type of drug delivery 
system designed from ELPs.   The objective of a study conducted by Adams et al. was to 
develop an injectable drug containing ELP depot, from which an antibiotic drug could be 
slowly released over time. [22]  In this study an ELP containing a large percentage of 
lysine residues was crosslinked to form an injectable gel.  After crosslinking, the gel was 
loaded with two antibiotics and drug release studies were performed.  For both 
antibiotics, cafazolin and vancomycin, the data from the release study showed sustained 
release over 25 and 520 hours respectively. 
 While some examples in literature include the loading of elastin-like polypeptides 
with drug molecules other studies were conducted to show their potential use as an 
effective drug delivery platform.  Certain types of ELPs have been shown to self 
assemble into micelles of nanoscale size when heated above their transition temperature.  
Ghoorchian et al. constructed and characterized a three armed star ELP that possesses the 
ability to form micelles under high pH and low NaCl concentration. [6]  This ELP, 
named H40-foldon, is composed of 40 GVGVP pentapeptide blocks attached to a foldon 
domain headgroup.  When an aqueous solution of H40-foldon is heated above its 
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transition temperature, spherical micelles of approximately 30 nm in diameter are 
produced.  The miceller architecture consists of an interior composed of the hydrophobic 
ELP and an exterior decorated by the foldon headgroups. [23]  The authors of this study 
did not drug load these particles, but do suggest their use as a potential drug delivery 
vehicle. 
 
1.2   Solute Partitioning 
 When a solute is distributed at constant temperature and pressure between 
multiple solvent phases equilibrium is established when the chemical potential of each 
species is identical in all phases. [24]  The chemical potential of a solute species, µ, in a 
two phase system, 𝛼 and β, can be represented by: 
 µα = µα
o + (RT)ln⁡(𝑓α) (1.6) 
 µβ = µβ
o + (RT)ln⁡(𝑓β) (1.7) 
where µo is the standard state chemical potential and 𝑓is the solute activity.  The solute 
activity may be expressed as: 
 𝑓 = (γ)(X) (1.8) 
where γ is the phase specific solute activity coefficient and X is the phase specific solute 
concentration.  At equilibrium; Eq. (1.6), Eq. (1.7), and Eq. (1.8) may be combined and 
written as Eq. (1.9). 
 µα
o − µβ
o = (RT)ln⁡(
(γβ)(Xβ)
(γα)(Xα)
) (1.9) 
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As a solute concentration approaches infinite dilution, the solute/solvent system behaves 
more ideally and the activity coefficient approaches 1.  Assuming an ideal solution, the 
Gibbs free energy of transfer for a solute molecule from solvent phase 𝛼 to phase β takes 
the form: 
 
ΔGtr(α→β)
RT
= ln (
Xβ
Xα
) = ln⁡(K) (1.10) 
where K is the partition coefficient of the solute defined as the ratio of solute 
concentrations between both solvent phases at equilibrium. 
 
1.2.1   Methods to determine the partition coefficient 
 The partition coefficient, K, is defined as the ratio of solute concentrations 
between two phases at equilibrium, Eq. (1.11).  Zaslavsky describes two methods 
 𝐾β/α =
[Solute]β
[Solute]α
 (1.11) 
for the determination of the solute partition coefficient. [25]  Both methods begin with 
the addition of the solute to be partitioned to a two-phase solvent system at the desired 
temperature.  After mixing to aid in dissolution of the solute and transfer between the two 
phases, the solvent system is allowed to phase separate for 12-24 hours or alternatively 
centrifuged for a shorter period of time. 
In the first method, described by Zaslavsky, the above procedure is performed 
several times using a fixed amount of solute introduced into the system.  After phase 
separation the solvent phases are analyzed and the solute partition coefficient is 
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determined.  In the second method, the partitioning procedure is performed by varying 
the amount of solute added to the solvent system.  Usually, four or five different amounts 
of solute are added to separately prepared solvent systems of the same composition.  
After phase separation the solvent phases are analyzed and the partition coefficient of the 
solute is determined by standard linear regression analysis, defined as the slope of the 
linear regression line: 
 [Solute]β = 𝐾[Solute]α + 𝑏 (1.12) 
where [Solute] is the concentration of solute within the respective solvent phase, 𝛼 and 𝛽.  
Using this method to calculate K determines if additional interactions are present that 
influence the partition process.  These additional interactions cause a deviation from the 
linear behavior described by Eq. (1.12).  Zaslavsky showed this deviation from linear 
behavior while studying the partitioning of egg white lysozyme in an aqueous two-phase 
solvent system. [25]  When lysozyme was partitioned in an aqueous Dex-Ficoll two-
phase system containing 0.11 mole/Kg sodium phosphate buffer at pH 7.40, significant 
deviation from linearity was observed.  Partitioning of lysozyme was also performed in 
the same solvent system containing 0.01 mole/Kg universal buffer at pH 4.4, where linear 
behavior was observed.  These results were explained by the dimerization of lysozyme at 
alkaline pH, resulting in the observed deviation from Eq. (1.12) due to additional 
interactions affecting the partitioning behavior. [26] 
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1.2.2   Solute partitioning models 
 Using solute partition coefficients, many models have been developed to describe 
the behavior of membrane transfer [27, 28], to determine relative hydrophobicity of 
organic compounds [29], to model chromatographic retention time [30, 31], to describe 
surface adsorption [32], and to predict solute solubility [33, 34, 35].  Abraham et al. has 
developed a solute partitioning model called a linear free energy relationship (LFER), Eq. 
(1.13), by describing the logarithm of the solute partition coefficient as a linear 
combination of several interaction parameters, where logSP is the logarithm of a solute 
property typically the solute partition coefficient; E, S, A, B, and V are solute descriptors; 
and e, s, a, b, and v are solvent descriptors (Table 1.3). [35, 36, 37, 38, 33] 
 log SP = eE + sS + aA + bB + vV + c (1.13) 
Table 1.3   Solute and Solvent Descriptors for Abraham’s Linear Free Energy Relationship 
Solute Descriptor Description 
E The excess molar refractivity parameter in units of (cm3 mol-1)/10. 
S The solute dipolarity/polarizability descriptor. 
A The solutes overall hydrogen bond acidity descriptor. 
B The solutes overall hydrogen bond basicity descriptor. 
V The McGowan characteristic volume in units of (cm3 mol-1)/100. 
  Solvent Descriptor Description 
e 
Describes the solvents ability to interact with a solute through π- 
and n-electron pairs. 
s 
Related to the difference in solvent dipolarity/polarizability between 
the phases. 
a 
Related to the difference in solvent hydrogen bond acceptor basicity 
between the phases. 
b 
Related to the difference in solvent hydrogen bond doner acidity 
between the phases. 
v 
Describes the solvents ability to interact with a solute by dispersive 
forces and/or the energy required to create a cavity in the solvent 
phase. 
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In the LFER, the solute descriptor E is the excess molar refractivity and refers to 
interactions through π- and n- electron pairs. [31]   This descriptor is calculated as the 
difference between, the molar refraction of the solute calculated using McGowan’s 
characteristic volume (MRx), and the molar refraction of an alkane with the same 
McGowan volume (MRx)alkane, Eq. (1.14).  To calculate MRx, Eq. (1.15), uses the 
McGowan characteristic volume (Vm) and, for liquids, the solute index of refraction or, 
for solids, the hypothetical index of refraction (η). [39] 
 E = MRx − (MRx)alkane (1.14) 
 MRx = 10(
η2−1
η2+2
)(
Vm
100
) (1.15) 
 (MRx)alkane = (2.83195)(
Vm
100
) + 0.52553 (1.16) 
 The solute descriptor V is the McGowan characteristic volume.  This descriptor is 
a representation of the energy required to separate solvent molecules and create a cavity 
of suitable size to accommodate the solute. [40]  Numerical values of this descriptor are 
often much larger than the values for the other descriptors in the LFER equation.  
Therefore, in the LFER equation this descriptor is scaled and used as V/100.  To calculate 
the McGowan characteristic volume all that is needed is the compound’s molecular 
structure and the list of characteristic atomic volumes determined by Abraham and 
McGowan. [40]  From the compound’s molecular structure, the number of each specific 
atom and the total number of bonds can be determined.  The McGowan volume is 
calculated by summing, for all atom types, the product of the number of atoms multiplied 
by its characteristic atomic volume then subtracting the total number of bonds multiplied 
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by 6.56 cm3 mol-1, Eq. (1.17).  It should be noted that in the calculation of the McGowan 
volume, the number of bonds are multiplied by 6.56 cm3 mol-1 no matter whether they are 
single, double, or triple bonds. 
 V = ∑(#of⁡atoms)(charcteristic⁡atomic⁡volume) − (#⁡of⁡bonds)(6.56)   (1.17) 
 
Table 1.4   Selected McGowan Characteristic Atomic Volumes [40] 
Element Characteristic Atomic Volume (cm3 mol-1) 
Carbon 16.35 
Hydrogen 8.71 
Oxygen 12.43 
For each bond between atoms, 6.56 cm3 mol-1 is to be subtracted 
 
For example, phenol is a simple aromatic compound with the molecular formula C6H6O 
(Figure 1.3) and contains a total of 13 bonds.  Thus, for phenol V is calculated as 77.5 
cm3 mol-1. 
 
 
Figure 1.3   Molecular structure of phenol 
 
V = (6)(16.35) + (6)(8.71) + 12.43 − (13)(6.56) = 77.5 
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 The S descriptor is a measure of the solutes ability to interact in dipole-dipole and 
dipole-induced dipole interactions while the A and B descriptors represent the interactions 
of hydrogen bond acidity and hydrogen bond basicity respectively.  These three 
descriptors can be obtained from gas liquid chromatography measurements, water-solvent 
partitioning, and molecular modeling. [41, 42, 43]  Currently, with the vast number of 
Abraham solvent and solute descriptors available, the solute descriptors (S, A, and B) can 
be obtained through multiple linear regression using Eq. (1.13).  This method is 
commonly employed to determine solute descriptors when solubility data for the solute is 
known.  For example, Bradley et al. calculated the S, A, and B Abraham solute 
descriptors for trans-cinnamic acid (CA) from published solubility data of (CA) in 26 
solvents all of which have Abraham solvent parameters (e, s, a, b, c). [44]  This group 
began by calculating the E and V descriptors from chemical structure by comparison with 
other structurally similar compounds, such as ethyl benzoate, benzoic acid, and ethyl 
cinnamate.  Next, a total of 45 LFER equations were constructed by combining the 
solubility data with (CA) partition coefficients measured in several different solvent 
systems.  Finally, these LFER equations were solved by regression to determine the 
values of S, A, and B that gave the best fit of experimental and calculated properties.  The 
final results from this group showed that unknown Abraham solute descriptors can be 
calculated from measured solute solubility in several solvents provided that the Abraham 
solvent descriptors for these solvents are available.  An identical procedure as that above 
has been applied by other authors with similar results. [45, 46] 
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1.3   Liquid Chromatography 
In the early 1900’s Russian botanist, Mikhail S. Tswett focused his study on the 
separation of leaf pigments obtained from plant material by solvent extraction. [47]  His 
experiments centered on using a glass tube or column packed with fine particles of 
calcium carbonate to perform the separation of the pigments. [48]  The experiment was 
performed by using slight pressure or suction to flow a solvent through the packed 
column until the particle bed was equilibrated.  Next the plant extract was applied to the 
column inlet, once the extract passed into the particle bed additional solvent was used to 
move the material through the column.  What resulted was the separation of the leaf 
pigments into different colored bands as they passed through the column packing.  What 
was born was a new separation technique based upon the different interactions of a solute 
with a liquid and solid phase.  This technique was called liquid chromatography. 
 
1.3.1   Advantages of Liquid Chromatography 
Analytical liquid chromatography is a technique used in analytical chemistry to 
separate a matrix into its individual components for quantitative and/or qualitative 
analysis.  With analytical techniques such as UV-VIS spectroscopy, the total absorption 
signal is the sum of the absorptions for all species present including the matrix 
background.  For the quantification of an analyte by UV-VIS spectroscopy, previous 
knowledge of sample composition is required.  Using this knowledge all background 
interferents can be subtracted from the total absorption signal, leaving the contribution to 
the signal from the analyte of interest.  This remaining absorption signal can then be used 
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for quantification of the analyte.  While this procedure works well for a simple matrix of 
one or two components, more complex matrices require an additional dimension to the 
analysis.  This additional dimension is usually in the form of a separation of the matrix 
analytes before analysis.  Using liquid chromatography to perform this separation has the 
advantage of separating the matrix into individual components for evaluation separately.  
This usually results in an increase in sensitivity and a lower limit of detection.  
Additionally, with the use of chromatography routine evaluation of more complex 
samples, such as biological fluids, is possible. 
 
1.3.2   Industrial uses of Liquid Chromatography 
Since Tsweet’s experimentation on the separation of plant pigments, liquid 
chromatography has proven to be a versatile and robust method for the quantification of 
simple and complex sample matrices.  This versatility is displayed by the large range of 
industries that have adopted this technique as a standard method of analysis.  The 
pharmaceutical and chemical processing industries commonly use liquid chromatography 
during the synthesis of pharmaceutical drugs and other chemical commodities. [49]  
Liquid chromatography provides these industries with the ability to determine when a 
chemical reaction is complete and what reaction impurities were produced.  With this 
information companies can determine when problems arise and how to correct them 
before a dangerously contaminated product enters the consumer market. 
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1.3.3   Chromatography Theory 
The separation of analytes by liquid chromatography relies on the difference in 
analyte interaction between the stationary and mobile phases.  A typical chromatographic 
process is depicted in Figure 1.4 [50]. 
 
 
Figure 1.4   Chromatographic process showing the separation of a two component 
mixture as it travels through a chromatography column.  Figure modified from reference 
[50]. 
 
In Figure 1.4 at time to, a two component mixture is introduced onto a liquid 
chromatography column then, a continuous supply of mobile phase is introduced to 
transport the analyte material through the column.  As the compounds move through the 
chromatographic column they partition between the stationary and mobile phases 
determined by their relative affinity for each phase.  If a compound has a stronger 
interaction with the stationary phase, then that compound will spend a greater proportion 
of its time on the column adsorbed to the stationary phase.  Since the velocity of the 
stationary phase is zero these compounds move through the column slowly.  The opposite 
is true for compounds with a stronger mobile phase interaction.  These compounds spend 
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a greater proportion of their time on the column within the mobile phase.  Compounds 
within the mobile phase move at the mobile phase velocity resulting in rapid migration 
through the column.  In Figure 1.4, the differences in relative interaction begin to show at 
time t1 by separation of the sample matrix into its individual components A and B.  
Shown in Figure 1.4, compound A has a greater relative affinity for the stationary phase 
while compound B has a greater relative affinity for the mobile phase. 
 
Column Efficiency and Band Broadening 
 Under ideal conditions analytes will move through the column without diffusional 
migration.  But, under real conditions analyte diffusion occurs resulting in the spreading 
of the analyte bands (Figure 1.4).  In column chromatography this spreading is called 
band broadening.  An important goal in liquid chromatography is to produce sharp, 
symmetric, and well resolved peaks as these factors aid in a more accurate calculation of 
peak area.  The sharpness of the chromatographic peaks represent the efficiency of the 
chromatographic column or, more correctly, the entire chromatographic system [50].  An 
increase in band broadening results in a decrease in column efficiency by reducing the 
sharpness of the analyte peak.  Therefore, efficiency can be used as a measure of the 
broadening of the sample zone as it passes through the chromatographic system [50]. 
The theoretical plate number N is a measure of column efficiency, where 𝑡𝑟 is the  
 𝑁 = 5.54[
𝑡𝑟−𝑡𝑚
𝑤ℎ/2
]2 (1.18) 
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analyte retention time, 𝑡𝑚 is the system dead time, and 𝑤ℎ/2 is the analyte peak width at 
one-half the peak height.  As shown in Figure 1.5, all of these variables are easily 
obtained from the chromatogram.  For the same chromatographic system the column  
 
 
Figure 1.5   Liquid chromatogram showing dead time, tm, analyte retention time, tr, and 
peak width at one-half peak height, wh/2. 
 
efficiency N is a function of the column length.  Since column length is not directly 
defined in Eq. (1.18), comparing column efficiency for two columns of different length or 
type becomes difficult.  To describe the relation between column efficiency and column 
length a new parameter is defined. 
 𝐻𝐸𝑇𝑃 =
𝐿
𝑁
 (1.19) 
This parameter, known as the theoretical plate height HETP, combines a measurement of 
column length L with column efficiency N.  Since column length is now defined as a 
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variable, HETP is commonly used to compare columns of different size or stationary 
phase type. 
 
Plate Theory 
Two theories exist that attempt to describe the chromatographic process and its 
relation to column efficiency.  The first theory, called plate theory, describes the 
chromatographic process analogous to a distillation column.  As with a distillation 
column, this theory describes the chromatographic system as a series of stages or 
theoretical plates.  At each stage analyte equilibrium occurs between two phases.  In 
distillation this is called vapor/liquid equilibrium.  In liquid chromatography this is the 
analyte equilibrium established between the stationary and mobile phases.  Plate theory 
uses Eq. (1.19) to measure column efficiency.  The largest shortcoming of plate theory is 
its failure to relate column efficiency to chromatographic variables such as stationary 
phase particle size and mobile phase flow rate. [50]  While plate theory has been 
criticized because of this defect it none the less still provides an easily calculated and 
useful parameter to measure column efficiency. 
 
 Rate Theory 
Since plate theory suffers from the failure to relate column efficiency to important 
chromatographic variables, a second theory based on kinetic characteristics was 
developed.  This theory, called rate theory, attempts to relate band broadening to the 
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HETP using a kinetic model.  This model focuses on the contribution of various kinetic 
parameters to the band broadening concept. 
 𝐻𝐸𝑇𝑃 = 𝐴 +
𝐵
𝑢
+ 𝐶 (1.20) 
Equation (1.20) is the van Deemter equation, written as the sum of three contributing 
terms to the HETP.  In this form of the equation, u is the mobile phase average linear 
velocity, the A term represents the contribution to band broadening from eddy diffusion, 
the B term represents the contribution from longitudinal diffusion, and the C term 
represents the contribution from resistance to mass transfer within the two phases. 
 
Van Deemter Plot 
From an analysts point of view, probably the most useful concept is a 
combination of both plate and rate theories.  Calculation of HETP using rate theory, Eq. 
(1.20), is not trivial, but rate theories relation of HETP to the mobile phase velocity is 
insightful since mobile phase flow rate is a variable that can be optimized to a particular 
chromatographic analysis.  Plate theory uses a simple calculation of HETP, Eq. (1.19), 
using parameters obtained directly from the chromatogram.  Therefore, in chromatogram 
parameter optimization analysts typically use a combination of both theories in the 
construction of a graph known as the van Deemter plot. [51, 49]  The van Deemter plot is 
a graph of plate height as a function of mobile phase linear velocity or mobile phase flow 
rate (Figure 1.6). 
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Figure 1.6   Hypothetical Van Deemter plots for various stationary phase particle sizes. 
 
The graph shown in Figure 1.6 is a van Deemter plot constructed by calculating HETP 
using Eq. (1.19) then graphing HETP as a function of mobile phase velocity.  Shown in 
Figure 1.6 for the 10 µm curve, this curve passes through an optimum average linear 
mobile phase velocity, uopt, at which HETP is at a minimum.  Since analysis time is 
proportional to mobile phase velocity, it is common for analysts to operate at mobile 
phase velocities greater than the optimum [50, 52].  By operating at greater velocities 
analysis time is reduced resulting in faster data acquisition, lower mobile phase 
consumption, and reduced operator time. [49] 
Additional efforts to reduce analysis time without sacrificing separation efficiency 
may be determined by comparing van Deemter plots as a function of stationary phase 
particle size. [53, 54]  The hypothetical van Deemter plots in Figure 1.6 show the relation 
between particle size, optimum mobile phase flow rate, and HETP.  As shown, a decrease 
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in stationary phase particle size results in a reduced effect of mobile phase velocity on 
HETP.  This is represented by a curve of lower slope at greater mobile phase velocities.  
Also, a decrease in HETP (i.e. an increase in column efficiency) is typically observed as 
particle size decreases (Figure 1.6).  These effects have been attributed to a solute 
experiencing a shorter diffusion path length while within the stationary phase particle. 
[55]  This shorter path length results in less time spent within the stationary phase particle 
where band broadening occurs.  Analysts use this relation between particle size and 
column efficiency to reduce analysis time and increase sample throughput. [56, 57]  Due 
to the increase in column efficiency with the use of smaller particles, shorter columns can 
be used. [58]  Also, smaller particles allow the separation to be performed at higher 
mobile phase flow rates.  By combining a shorter column operating at a greater flow rate, 
analysis time is significantly reduced resulting in increased sample throughput without a 
loss in efficiency.  
 
1.3.4   High Performance Liquid Chromatography 
High Performance Liquid Chromatography (HPLC) is a derivative of liquid 
chromatography that operates at high pressure.  The HPLC system is composed of: 
solvent delivery pumps, sample injection system, chromatography column, detector, and 
a computer that controls all operations (Figure 1.7). 
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Figure 1.7   Schematic diagram of an HPLC system. 
 
First, using a high pressure pump solvent from the solvent reservoir is pumped to 
a sample introduction system.  In the sample introduction system, the sample to be 
analyzed is injected into the solvent flow path and transferred to the inlet of a 
chromatography column.  The chromatography column separates the sample into its 
different components that individually exit the column.  From the column outlet the 
components enter a detector before finally traveling to a waste container.  From the 
detector a signal is sent to a computer where the chromatogram is generated. 
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 Solvent Delivery System 
The primary function of the solvent delivery system (SDS) is to deliver the 
mobile phase at a constant flow-rate or pressure.  Most commonly the SDS is operated at 
a constant flow-rate.  Many detectors used for HPLC are sensitive to pump pulsations.  
Therefore, for highly reproducible chromatograms, the construction of the solvent 
delivery pump must be such that it provides a flow-rate that varies by less than one 
percent.  To aid the pump in providing this level of consistency, many system 
manufactures include a damper as part of the solvent delivery system.  The solvent 
delivery system for HPLC systems consists of one or more high pressure pumps capable 
of delivering the mobile phase at backpressures up to 6000 p.s.i. [52]  Often the solvent 
delivery systems consist of two or more pumps, providing the user the ability to operate 
the chromatographic separation under gradient elution mode. [59, 60, 61, 62] 
 
Sample Injection System 
 The function of the sample introduction system is to introduce the sample into the 
chromatography system in such a way as to reduce disturbance of the solvent flow, as this 
may result in chromatogram baseline disruption.  There are two types of sample 
introduction systems for HPLC instrumentation: manual and automated injection.  To 
perform the injection process both types of injection systems use a sample loop 
connected to a high-pressure injection valve. 
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Figure 1.8   Schematic diagram of Ryeodyne 7725i injection valve in both load and inject 
positions.  Figure modified from reference [63]. 
 
   The injection procedure begins by rotating the injection valve into the sample load 
position.  In this position the mobile phase bypasses the sample loop and flows directly to 
the column.  Once sample is loaded into the sample loop the injector is rotated to the 
inject position.  In this position the sample loop is placed back into the mobile phase flow 
path allowing the sample to be transferred to the column inlet. 
 For manual injection valves loading the sample loop is performed by the analyst 
using a sample needle specifically designed for the type of manual injector used.  During 
manual sample introduction, to increase precision between samples, the analyst should 
flush the sample loop with five sample loop volumes before the complete loop volume is 
injected into the system. 
 Analytical labs need the ability to program the instrumentation to run numerous 
samples concurrently without requiring the analyst to inject each sample.  Therefore, 
most HPLC systems used in industry are equipped with an autosampler.  The autosampler 
offers an advantage over manual injector type systems since analyst supervision is 
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reduced allowing the analyst to concentrate on other laboratory duties.  For HPLC 
systems integrated with an autosampler, sample injection is performed by the 
instrumentation.  First, the analyst fills an autosampler vial with the sample which is then 
placed into the autosampler carousel.  Next, the sample location and sample data are 
programmed into the HPLC control software.  When the run begins the autosampler 
selects the proper sample, washes the needle with wash solvent followed by a 
programmed amount of sample, then fills the sample loop, and injects the sample into the 
mobile phase flow path.  The typical sample loop volume installed on an autosampler is 
100 µL, but it is more common to inject sample volumes less than 100 µL.  Therefore, 
most autosamplers have the option of a partial sample loop fill mode.  Partial sample loop 
fill mode is the most commonly used sample introduction mode however, using this 
mode results in a loss in precision when compared to complete fill mode.  For complete 
fill mode the precision is typically in the range of 0.05 to 1% relative standard deviation, 
while in the partial fill mode precision drops in the range of 0.2 to 2%. [50] 
 
Chromatography Column 
 The function of the chromatography column is to separate the sample into its 
individual compounds.  Chromatography columns are constructed from a polymer 
(PEEK) or stainless steel tube packed with a stationary phase.  HPLC is a versatile 
method with the ability to operate in several different types of modes, dependent on the 
type of stationary phase used.  The operational mode is characterized by the relative 
hydrophobicity of the mobile and stationary phases.  The two most common operational 
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modes are: normal and reverse phase chromatography.  Normal phase chromatography is 
characterized by the stationary phase being less hydrophobic than the mobile phase, 
while reverse phase mode is characterized as the stationary phase being more 
hydrophobic than the mobile phase. 
 In normal phase chromatography the stationary phase is a polar material such as 
silica gel.  Common solvents used in normal phase chromatography are non-polar 
solvents such as: esters, ethers, alkanes, or chlorinated hydrocarbons. [64]  During normal 
phase chromatography compounds are separated by their dipole interactions with the 
stationary phase.  Therefore, solute compounds that are highly polar will spend a greater 
proportion of their time on the column within the stationary phase resulting in a longer 
retention time. 
 
 
Figure 1.9   Hypothetical silica stationary phase bead where R is the modified functional 
group. 
 
In reverse phase chromatography the stationary phase is the same type of silica 
gel support used in the construction of normal phase columns, but the support has been 
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functionalized to alter its polarity (Figure 1.9).  Typical support alterations include the 
addition of a C18, C8, or C4 hydrocarbon chain to produce siloxane reverse phase 
packings. 
 
Table 1.5   Common Types of Modified Silica HPLC Stationary Phases  
Functional group name R= 
C18 CH3-(CH2)17- 
C8 CH3-(CH2)7- 
C4 CH3-(CH2)3- 
Phenyl-Hexyl 
 
Pentafluorophenyl (PFP) 
 
Cyanopropyl 
 
Amino 
 
 
With such a large assortment of stationary phases commercially available (Table 
1.5), an analyst can alter the selectivity of a given separation by simply changing the type 
of stationary phase used. [62, 65, 66, 67]  This ability to alter selectivity results in 
enhanced flexibility for reverse phase chromatography compared to normal phase 
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operation.  For this reason reverse phase mode is the most widely used of all liquid 
chromatographic modes. 
 
Detectors 
 The function of the detector is to monitor the chromatographic run and output a 
signal to the control computer for the construction of the chromatogram.  Due to the use 
of computer control, an advantage of HPLC is its ability to be connected to various types 
of detectors.  Typical HPLC detectors include the UV-VIS, diode array, fluorescence, and 
mass spectrum detectors.  The two most common HPLC detectors are the UV-VIS and 
diode array detector. 
The HPLC UV-VIS detector operates by the same principals as a common UV-
VIS spectrometer.  For a UV-VIS spectrometer light intensity and concentration are 
related by the Beer-Lambert Law:  
 A = εbC (1.21) 
where A is the absorbance of the sample, b is the optical path length, ε is the molar 
extinction coefficient of the solute at the measuring wavelength, and C is the molar 
concentration of the solute. [50]  At a fixed wavelength, the relationship between 
absorbance and concentration is linear, but this relationship is valid only when truly 
monochromatic light is used.  Most UV-VIS spectrometers and HPLC detectors use a 
mercury vapor or deuterium lamp as the light source.  These light sources are not 
monochromatic, therefore a slit is used to filter the light into a narrow range of 
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wavelengths centered on the wavelength of interest.  This filtering results in a short range 
of wavelengths instead of a monochromatic signal.  Since the source signal is not 
monochromatic it is recommended to operate the detector in wavelength regions where ε 
changes very little; that is, at maxima, minima, or shoulders in the absorption spectrum of 
the solute of interest. [50] 
 
 
Figure 1.10   Schematic diagram showing diode-array detector optics.  Figure modified 
from reference [68]. 
 
 The diode-array detector is an absorption detector capable of simultaneously 
monitoring all wavelengths between 190 and 800 nm.  The arrangement of the optics for 
a diode array detector is shown in Figure 1.10.  From the output of the chromatographic 
column, the effluent passes through a flow cell.  Using a series of lenses polychromatic 
light from a deuterium lamp is focused onto the flow cell.  Light passes through the flow 
cell and sample to a holographic diffraction grating then is dispersed onto the diode array.  
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This array consists of several hundred photosensitive diodes configured in a linear pattern 
which mimics the focal plane of the spectrometer. [50]  A capacitor is connected to each 
diode which is initially charged to a known level.  Light falling on the diode discharges 
the capacitor to a level in relation to the intensity of the light.  To generate a 
chromatogram the signal intensity from each diode in the array is plotted as a function of 
wavelength and analysis time (Figure 1.11). 
 
Figure 1.11   Example chromatogram obtained from an HPLC diode-array detector. 
 
Using this type of detector offers several advantages compared to single 
wavelength monitoring.  For example, the chromatogram can be used to determine peak 
purity. [50]  If a UV-VIS absorbance spectrum of the pure analyte of interest can be 
obtained, this spectrum can be compared to that obtained from the analyte peak on the 
diode-array chromatogram.  Any differences in relative absorbance may indicate the 
presence of co-eluting analytes. 
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CHAPTER II 
OBJECTIVE 
Elastin-like polypeptides (ELPs) are a class of biopolymers with the potential to 
function as a drug delivery platform.  Recently, this class of polymers has been expanded 
by the addition of a trimer forming oligomerization domain, called foldon, to the C-
terminus of an ELP chain (Figure 2.1). [6]  The addition of this domain resulted in the 
development of a three-armed star ELP that has been shown to self assemble into 
micelles on the nanometer scale when the solution temperature was raised above its 
transition temperature. [23] 
 
 
Figure 2.1   Three-armed star elastin-like polypeptide. 
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The micellar architecture of this new construct consists of a spherical shape with an outer 
surface decorated by hydrophilic foldon domains and an interior core consisting of the 
hydrophobic elastin-like polypeptide (Figure 2.2).  Once the micelle core is loaded with 
therapeutic, these loaded particles potentially have the ability to slowly release the 
compound from the core into the surrounding environment. [69, 70] 
 
 
Figure 2.2   Micelle structure of Foldon-ELP showing micelle core consisting of ELP. 
 
For the use of this micellar construct as a drug delivery platform, solute solubility 
within the micelle core should be investigated.  Information gathered from this study may 
be used to characterize the micelle interior and determine the required ELP 
hydrophobicity or amino acid composition necessary for the extended release of 
therapeutic compounds. 
Since the micelle interior consists predominantly of ELP this study uses the 
coacervate phase of linear ELPs to investigate solute solubility within the micelle core.  
This investigation is conducted by mixing aqueous solutions of ELP with small molecule 
 41 
 
solutes, then the system temperature is raised above the solution transition temperature to 
cause phase separation.  The resulting two-phase system consists of a protein poor upper 
“supernatant” phase at equilibrium with a lower protein rich “coacervate phase” (Figure 
1.1).  Next, the phases are separated and solute concentration in each phase is analyzed 
using high performance liquid chromatography.  The partition coefficient of each solute 
is calculated and reported as the ratio of solute concentration in the protein rich 
coacervate phase to that of the protein poor supernatant phase. 
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CHAPTER III 
MATERIALS AND METHODS 
 
3.1   Protein Synthesis and Purification 
3.1.1   Protein Synthesis 
All chemicals were purchased from Fisher Scientific.  Protein expression media 
used in this study was Lysogeny Broth (LB).  This media was formulated with the 
composition: 5 g/L yeast extract, 10 g/L peptone, 5 g/L sodium chloride then filled to the 
required volume using deionized water.  Media sterilization was performed using a steam 
autoclave (Cycle: 121oC for 45 min).  The selection agent used in this media was 
ampicillin at a concentration of 100 mg/L. 
Initial protein synthesis was performed on a 1 L expression scale.  Since 
partitioning experiments required between 6 and 18 liters of expression media, protein 
expression volume was increased to 6 L.  The typical protein expression protocol began 
by preparing a starter culture from LB media inoculated with the appropriate frozen 
glycerol stock culture.  After overnight incubation at 37oC on a shaker table (250 rpm), 
the starter culture was used to inoculate a larger quantity of LB media.  This media was 
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incubated at 37oC on a shaker table (250 rpm) while monitoring the growth rate using a 
UV-VIS spectrometer (λ = 600 nm).  Once the desired cell density (OD600 = 0.8 to 1.2) 
was achieved the culture was induced using isopropyl β-D-1-thiogalactopyranoside 
(IPTG).  Induction was allowed to proceed for a minimum of 5 hours then bacteria were 
isolated by centrifugation (20oC, 10,000xg, 10 min).  A more detailed description of both 
the 1 L and 6 L expression procedures are outlined in Appendix A. 
 
3.1.2   Protein Extraction and Purification 
After isolation of the bacteria, the pellet was resuspended in deionized water, 
cooled in an ice bath below 10oC, and pulse sonicated (550 Sonic Dismembrator, Fisher 
Scientific) using the pulse sequence of: 10 s on (100% power) then 20 s off while keeping 
the solution temperature below 10oC.  Following sonication the protein was purified by 
inverse transition cycling (ITC). [71]  A typical round of ITC protocol began by cooling 
the protein solution below 5oC using an ice bath, then centrifuging cold (3oC, 20,000xg, 
20 min) to remove insoluble material.  Next, the protein solution was decanted from the 
insoluble material, then the decanted solution temperature was raised to 55oC and held at 
this temperature for 30 minutes, causing the protein to separate from solution.  Finally, 
the protein pellet was isolated by hot centrifugation (40oC, 20,000xg, 10 min), 
completing one round of ITC.  Typically, three rounds of ITC were performed using the 
resuspension volumes of 15, 5, and 1 mL/L culture for each subsequent cycle.  
Occasionally, sodium chloride was added and solution pH was adjusted to aid in protein 
purification.  A complete description of the protein purification procedure is outlined in 
Appendix B.  After protein purification, protein solution purity was determined by 
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HPLC.  Typical solution purity after three rounds of ITC was greater than 95%.  Final 
protein solution concentration was determined by UV-VIS spectroscopy measured at 280 
nm using the calculated extinction coefficient (Table 3.1). 
 
Table 3.1   Amino Acid Sequences for all Proteins Investigated along with their 
Molecular Weight and Extinction Coefficient at 280 nm 
Protein 
construct Amino acid sequence 
Molecular weight 
(g/mole) 
Extinction coefficient 
@ 280 nm (M-1 cm-1) 
(GVGVP)40 MGH-(GVGVP)40-GWP 17,066 5,500 
(LQQ)12 
MGH-(GLGVP-GQGVP-
GQGVP)12-GWP 16,290 5,500 
(V3(VH)3)4 
MGH-[(GVGVP)3-(GVGVP-
GHGVP)3]4 15,881 5,500 
 
3.2   Solutes Investigated 
 To aid in detection by UV-VIS spectroscopy, the solutes investigated in this study 
(Figure 3.1) were selected according to two criteria.  First, all solutes should have a water 
solubility greater than or equal to 1 mg/mL and second, all solutes should posses a high 
extinction coefficient. 
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Figure 3.1   Structures for all compounds investigated in this study. 
 
3.3   Master Stock Solute Solution Preparation 
 A master stock solute solution of the investigated compounds was prepared by 
dissolving each compound into water at concentrations of approximately 1 to 5 mg/mL. 
This master stock solute solution was used for all partitioning experiments in this study.  
The solute compounds 5-fluorouracil, acetaminophen, and 4-nitrophenol were purchased 
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from Acros Organics.  Vanillin, phenol, ethyl paraben, and piperonal were purchased 
from Alfa Aesar. 
 
3.4   Partition Coefficient Calculation Procedure 
 The partition coefficient, K, is defined as the ratio of the solute concentration in 
the lower coacervate phase to the solute concentration in the upper supernatant phase, Eq. 
(1.11).  To calculate the partition coefficient for each compound a plot of compound peak 
area in the coacervate phase as a function of compound peak area in the supernatant 
phase, obtained by HPLC, was constructed.  The partition coefficient was determined as 
the slope of a linear regression line of best fit. 
 
3.5   Partitioning 
 Partitioning experiments were performed by varying the solute concentration at a 
fixed protein concentration (1 mM protein concentration) and system temperature (37oC 
or 55oC).  Both PBS (0.15 M NaCl, 0.01 M Na3PO4, pH 7.4) and water solvent conditions 
were explored.  All experiments were performed in duplicate according to the following 
procedure. 
The partitioning vessel was constructed from a 4 mm inside diameter glass 
nuclear magnetic resonance (NMR) tube cut to a length of 8.5 cm.  Protein solutions were 
prepared by diluting the desired protein stock solution to a final concentration of 1 mM 
protein in both 1.08xPBS and water.  Each partitioning experiment consisted of 
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measuring the partition coefficient at four different solute concentrations.  Therefore, four 
of the constructed NMR tubes were numbered and their individual masses measured 
using a microbalance.  After their masses were recorded each tube was charged with 500 
µL of the desired 1 mM protein solution.  Varying amounts of the master stock solute 
solution was added (10, 20, 30, and 40 µL) to each NMR tube followed by the 
complementary amount (30, 20, 10, and 0 µL) of water.  Next, each tube was sealed, 
moderately vortexed to ensure a well-mixed solution, then centrifuged for 2 min at 
2,000xg and 10-15oC.  
Phase separation was performed by placing the tubes in an incubator at a 
temperature above the solution transition temperature for approximately 18 hours.  For 
protein constructs (GVGVP)40 and (V3(VH)3)4, the incubator temperature was 37
oC; for 
protein construct (LQQ)12, the incubator temperature was 55
oC.  Once phase separation 
was complete all tubes were centrifuged (15 min at 2,000xg) at their respective system 
temperature. 
 Quickly, before significant cooling of the partitioned system, the top supernatant 
phase was removed using a glass pasture pipet, ensuring the bottom coacervate phase was 
not disturbed.  After removal of the supernatant phase a cotton swab was used to remove 
residual supernatant from the wall of the tube.  The total mass of the tube containing the 
coacervate was recorded then 500 µL of deionized water was added to the tube.  Once 
again the total mass of the tube was recorded, then the tube sealed.  Finally, the solution 
was cooled in ice, moderately vortexed to ensure a well-mixed solution, and transferred 
to an HPLC autosampler vial for analysis. 
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3.6   High Performance Liquid Chromatography Setup 
 Chromatographic methods were developed by analyzing the master stock solute 
solution and the desired protein solution separately then as a combined solution.  The 
HPLC system consisted of a two pump solvent delivery module (Beckman Coulter 
Model: System Gold 126 Solvent Module), an autosampler (Beckman Coulter Model: 
System Gold 508 Autosampler), and a diode array detector (Beckman Coulter Model: 
System Gold 168 Detector).  The separation was performed on a 250 x 5 mm I.D. (5 µm) 
reverse phase C18 Luna column (Phenomenex) with guard cartridge (Phenomenex 
Security Guard).  Injection volume was 20 µL for all analyses.  Mobile phase A 
composition was water:acetonitrile:trifluoroacetic acid (94.9:5:0.1, v/v/v) and mobile 
phase B composition was 100% acetonitrile.  Column effluent was monitored at a 
detector wavelength of 280 nm.  All chromatograms were collected at room temperature 
(20oC).  Data collection and instrument operation was performed by 32 Karat software 
(Beckman Coulter).  All HPLC mobile phase solvents were of HPLC grade and 
purchased from Fisher Scientific.  Chromatogram optimization was performed in an 
effort to reduce analysis time while providing well resolved and symmetric solute peaks. 
 
3.6.1   Mobile Phase Gradient Profile for the (GVGVP)40 Protein System 
The mobile phase profile (Figure 3.2-A) for protein system (GVGVP)40 started 
with a mobile phase composition of 32% B.  This composition was held for 8 minutes 
then increased to 55% B.  After 3.5 minutes at 55% B the column was re-equibrated at 
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32% B for 3 minutes.  Throughout the separation the mobile phase flow rate was 
maintained constant at 1.5 mL/min.  Total run time including re-equilibration period was 
14.5 minutes. 
 
3.6.2   Mobile Phase Gradient Profile for (LQQ)12 Protein System 
For protein system (LQQ)12 separation (Figure 3.2-B) was accomplished starting 
at an initial mobile phase composition of 10% B.  After holding at 10% B for 1.5 minutes 
the mobile phase composition was increased to 35% B followed by a linear gradient to 
40% B ending at 7 minutes.  The composition was held for 3 minutes at 40% B then re-
equilibrated for 3 minutes at 10% B.  Mobile phase flow rate was held constant at 1.5 
mL/min.  Total run time including re-equilibration was 13 minutes. 
 
3.6.3   Mobile Phase Gradient Profile for (V3(VH)3)4 Protein System 
Mobile phase composition (Figure 3.2-C) started at 15% B with a linear gradient 
programmed to increase composition to 50% B over 6 minutes.  Composition was held at 
50% B for 4 minutes then system was re-equilibrated for 3 minutes at 15% B.  Mobile 
phase flow rate was held constant at 1.0 ml/min.  Total run time including re-
equilibration period was 13 minutes. 
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Figure 3.2   Representative chromatograms and gradient profiles for solvent/protein 
systems: A. (GVGVP)40, B. (LQQ)12, and C. (V3(VH)3)4.  Solutes: (1) 5-flurouracil, (2) 
acetaminophen, (3) vanillin, (4) phenol, (5) 4-nitrophenol, (6) piperonal, (7) ethyl 
paraben, and (8) respective protein. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
 
 The partition coefficient, K, of a solute is defined as the ratio of solute 
concentrations between two phases at equilibrium.  Equation (4.1) shows the 
octanol/water partition coefficient where [Solute] is the solute concentration and the 
subscript ‘o’ and ‘w’ represent the composition of the respective phase. 
 𝐾𝑜/𝑤 =
[Solute]o
[Solute]w
 (4.1) 
In this study partition coefficients were determined for solvent systems composed of a 
protein rich coacervate (co) and protein poor supernatant phase (sn).  To keep the 
identical nomenclature as the octanol/water partitioning system, the partition coefficients 
measured in the investigated protein systems were defined as the ratio where the more 
water rich phase is the denominator, Eq. (4.2). 
 𝐾co/sn =
[Solute]co
[Solute]sn
 (4.2) 
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Since the solute peak area is proportional to concentration, solute calibration was 
not necessary.  When calculating the partition coefficients solute peak areas were used 
instead of solute concentrations, Eq. (4.3).  Two requirements are necessary to use peak 
area (or signal) from a detector as a replacement for concentration.  First, one must verify 
that solute peak area is linearly proportional to concentration over the range of interest 
and second, the intercept of the calibration curve used for detector signal to concentration 
conversion must be set to zero.  When these requirements are met, the slope of the 
calibration curve ‘m’ will cancel out of the equation during the calculation of ‘𝐾’ leaving 
only the ratio of detector signals, Eq. (4.3). 
 𝐾co/sn =
(𝑚)∗[𝑆𝑜𝑙𝑢𝑡𝑒]𝑐𝑜
(𝑚)∗[𝑆𝑜𝑙𝑢𝑡𝑒]𝑠𝑛
=
Solute⁡peak⁡area⁡in⁡coacervate
Solute⁡peak⁡area⁡in⁡supernatant
 (4.3) 
To check for detector linearity 11 concentrations of the master solute stock 
solution were analyzed by HPLC using the mobile phase gradient profile for (GVGVP)40.  
Linear regression was performed with the intercept set at zero then the correlation 
coefficient (r2) and slope were calculated (Table 4.1, Appendix C). 
 
Table 4.1   Results from HPLC DAD Detector Linearity Check at 280 nm Wavelength 
Compound Slope (105) r2 
Lowest Standard 
Area (103) 
Highest Standard 
Area (106) 
5-Fluorouracil 3.3 1.00 5.3 6.6 
Acetaminophen 1.7 1.00 2.7 3.3 
Vanillin 7.9 1.00 9.8 16 
Phenol 0.8 1.00 1.5 1.6 
4-Nitrophenol 3.0 1.00 3.6 5.9 
Piperonal 2.7 1.00 4.2 5.3 
Ethyl paraben 0.8 1.00 3.6 1.7 
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The correlation coefficient for all compounds shows a strong linear correlation between 
concentration and detector signal over the range investigated.  This result suggests using 
HPLC peak areas is a valid replacement for concentration to calculate partition 
coefficients. 
 After phase separation HPLC was used to measure solute peak area in the 
supernatant and coacervate phases.  The supernatant phase could be analyzed by HPLC 
without any further sample preparation, but since the coacervate phase volume was only 
10-15 µL and the phase viscosity is like that of room temperature honey, dilution of the 
coacervate phase was necessary before analysis.  Since the coacervate phase was diluted, 
it was necessary to record the initial coacervate mass and the final solution mass to back 
calculate the peak area in the undiluted coacervate, Eq. (4.4) and (4.5).  Since this 
 Solute⁡peak⁡area⁡in⁡coacervate =
(Solute⁡peak⁡area⁡in⁡diluted⁡coacervate)
Γ
 (4.4) 
 Coacervate⁡mass⁡fraction = Γ =
Coacervate⁡mass
Final⁡solution⁡mass
 (4.5) 
procedure involves the measuring of a small mass difference (i.e. the difference between 
the NMR tube with and without coacervate), it is possible that this procedure is more 
susceptible to error.  For example, the data presented in Table 4.2 are the measured 
masses of coacervate in milligrams for one partition experiment consisting of four sample 
tubes.  A high percent relative standard deviation (%RSD) is shown in the original data 
suggesting a large range in the measured values.  While this range could possibly be due 
to errors in experimental procedure, each sample tube was originally charged with an 
identical volume of the same protein solution.  Therefore, it is more likely that the high 
%RSD may be the result from error in one or both of the mass measurements used in the 
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calculation of the solute peak area in the coacervate.  Figure 4.1 is a plot of the solute 
peak area in the coacervate as a function of solute peak area in the supernatant for the 
 
Table 4.2   Measured Coacervate Masses for (V3(VH)3)4 protein system with PBS 
Sample Tube # 1 2 3 4 Average %RSD 
Original CO wt (mg) 16.5 17.1 14.1 15.5 15.8 8.3 
Distance from Average (mg) 0.7 1.3 1.7 0.3     
 
 
Figure 4.1   Plot of original data and averaged coacervate mass data for ethyl paraben in 
the (V3(VH)3)4 protein system with PBS. 
 
solute compound ethyl paraben.  As shown, in the original data the third data point does 
not follow the linear trend observed for all other data points in its series.  Since all sample 
tubes were charged with approximately the same volume of protein stock solution an 
average of the coacervate masses was used to recalculate the peak areas.  This resulted in 
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a better linear trend in the data suggesting error in the mass measurement is responsible 
for the variance in the original data.  Errors associated with the mass measurements also 
had an effect on the partition coefficient and its 95% confidence interval.  In the original 
data the partition coefficient for this solute was 9.21 with a confidence interval of 4.66.  
In the average adjusted data the partition coefficient and confidence interval were 
reduced to 8.38 and 0.92 respectively. 
To reduce measurement error an alternative method of calculating the solute peak 
area in the coacervate phase was explored.  This method utilizes the measured protein 
peak area in the coacervate sample along with the GRG nonlinear equation solver tool in 
Microsoft Excel to calculate the original coacervate mass.  The equation derivation 
begins with Eq. (4.4) and (4.5).  In the previous calculation method the coacervate mass 
fraction ‘Γ’ was calculated using the measured masses of both the final solution mass and 
coacervate mass.  In this method the coacervate mass fraction was determined by relating 
the mass fraction to the protein peak area (Figure 4.2). 
Figure 4.2 is a plot of (GVGVP)40 coacervate mass fraction as a function of 
protein peak area for 3 different sets of data measured at different times.  The difference 
in slope is attributed to the change in detector response at the time of analysis.  The 
purpose of Figure 4.2 is only to show how the slope changes between analyses.  In 
practice the slope from Figure 4.2 was not used in the calculation, but instead calculated 
as the correction factor ‘ξ’. 
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Figure 4.2   Plot of coacervate mass fraction as a function of (GVGVP)40 protein peak 
area for several data sets. 
  
Based upon the concept represented in Figure 4.2, Eq. (4.6) relates the protein 
peak area in the diluted coacervate sample to the coacervate mass fraction. 
 Γ = (ξ)(Protein⁡peak⁡area⁡in⁡diluted⁡coacervate) (4.6) 
By combining Eq. (4.4) and (4.6), Eq. (4.7) calculates the undiluted solute peak area from 
the diluted solute peak area and the protein peak area. 
 Solute⁡peak⁡area⁡in⁡coacervate =
(Solute⁡peak⁡area⁡in⁡diluted⁡coacervate)
(ξ)(Protein⁡peak⁡area⁡in⁡diluted⁡coacervate)
 (4.7) 
The final equation, Eq. (4.8), used for calculating the partition coefficient of a solute was 
derived by combining Eq. (4.3) and (4.7). 
 𝐾co/sn =
(Solute⁡peak⁡area⁡in⁡diluted⁡coacervate)
(ξ)(Protein⁡peak⁡area⁡in⁡diluted⁡coacervate)(Solute⁡peak⁡area⁡in⁡supernatant)
 (4.8) 
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In Eq. (4.8) all variables are obtained from the chromatogram except for the correction 
factor ‘ξ’.  This value was obtained iteratively using the procedure below. 
 To obtain the value of ‘ξ’ a reference solute was established.  For this study the 
reference solute was 5-fluorouracil. 
 The partition coefficient of the reference solute was calculated using Eq. (4.3), 
(4.4), and (4.5). 
 The Microsoft Excel GRG nonlinear equation solver was setup by fixing the 
target cell to the partition coefficient of the reference solute then changing the 
value of ‘ξ’ such that it satisfies Eq. (4.8).   
This value of ‘ξ’ was then used to determine all remaining solute partition coefficients for 
that set of data.  Since the slope of Eq. (4.6) is not a constant (Figure 4.2) a new value of 
‘ξ’ was calculated for each data set.  Results from using both the coacervate mass and 
protein peak area calculations are shown in Table 4.3 for the (GVGVP)40 protein solvent 
system.  Sample graphs for the two methods of calculation are presented in Figure 4.3. 
The results show the 95% confidence interval for all partition data using the 
protein peak area was narrower than that obtained from using the coacervate mass 
calculation (Table 4.3).  Since the confidence interval is narrower using the protein peak 
area method all further protein systems were evaluated using this method of calculation 
(Table 4.4). 
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Table 4.3   Comparison of Partition Coefficients and 95% Confidence Interval using the 
Coacervate Mass and Protein Peak Area Methods of Calculation 
        Calculation Method 
ELP Type 
 
Solute 
 
Coacervate Mass   Protein Peak Area 
(GVGVP)40 
 
5-Fluorouracil 1.03  (0.04) 
 
1.02  (0.03) 
  
Acetaminophen 4.66  (0.28) 
 
4.54  (0.14) 
  
Vanillin 
 
5.32  (0.29) 
 
5.12  (0.14) 
  
Phenol 
 
5.58  (0.43) 
 
5.01  (0.41) 
  
4-Nitrophenol 5.63  (0.31) 
 
5.42  (0.09) 
  
Piperonal 6.57  (0.28) 
 
6.37  (0.18) 
  
Ethyl paraben 15.1  (1.2)   14.2  (0.2) 
                95% Confidence interval displayed in parentheses 
 
 
 
Figure 4.3   Example results from (A) using coacervate mass and (B) protein peak area 
for calculation.  Solute was ethyl paraben in solvent system (GVGVP)40 with PBS. 
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Table 4.4   Final Results Table Displaying Partition Coefficients of Several Solutes in 5 
Protein/Solvent Two-Phase Systems 
        Composition   
    
Deionized water 
 
PBS pH 7.4 
 ELP Type  Solute  K(co/sn)   K(co/sn) n 
(GVGVP)40 5-Fluorouracil 1.18 (0.06) 
 
1.02 (0.03) 24 
  
Acetaminophen 3.88 (0.18) 
 
4.54 (0.14) 24 
  
Vanillin 
 
5.65 (0.28) 
 
5.12 (0.14) 24 
  
Phenol 
 
3.80 (0.27) 
 
5.01 (0.41) 24 
  
4-Nitrophenol 7.85 (0.44) 
 
5.42 (0.09) 24 
  
Piperonal 4.73 (0.25) 
 
6.37 (0.18) 24 
  
Ethyl paraben 12.2 (0.6) 
 
14.2 (0.2) 24 
          (V3(VH)3)4 5-Fluorouracil 1.18 (0.78) 
 
1.21 (0.13) 16 
  
Acetaminophen 2.22 (0.64) 
 
3.91 (0.22) 16 
  
Vanillin 
 
3.70 (0.73) 
 
4.43 (0.24) 16 
  
Phenol 
 
1.69 (1.57) 
 
4.09 (0.27) 16 
  
4-Nitrophenol 5.10 (0.34) 
 
5.02 (0.26) 16 
  
Piperonal 2.54 (0.57) 
 
5.04 (0.26) 16 
  
Ethyl paraben 4.82 (0.62) 
 
9.75 (0.51) 16 
          (LQQ)12 
 
5-Fluorouracil 
   
1.08 (0.04) 8 
  
Acetaminophen 
   
2.21 (0.32) 8 
  
Vanillin 
    
4.33 (0.83) 8 
  
Phenol 
    
4.77 (0.62) 8 
  
4-Nitrophenol 
   
2.94 (0.79) 8 
  Ethyl paraben       5.14 (0.35) 8 
             95% Confidence interval displayed in parentheses 
                  n is the number of data points used for data regression 
    
To further investigate the solvent phases, solvent descriptors were calculated 
based on the linear free energy relationship described by Abraham, Eq. (4.9). 
 log(K) = eE + sS + aA + bB + vV + c (4.9) 
This equation models five interaction parameters where E, S, A, B, and V are solute 
descriptors and e, s, a, b, v, and c are solvent descriptors.  To calculate the solvent 
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descriptors, the measured partition coefficients and the solute descriptors, obtained from 
literature (Table 4.5), were combined to generate six equations with the six solvent 
descriptors as unknowns.  These six equations were then solved for the solvent 
descriptors by minimizing an objective function, Eq. (4.10).  The calculated solvent 
descriptors serve to characterize the solvent system under investigation and in the case 
where the LFER describes a partitioning process, such as Eq. (4.9), the solvent 
descriptors represent the difference in properties of the two phases taking part in the 
partitioning process. [72] 
 objective⁡function = ∑(log⁡(K)fit − log⁡(K)exp)
2  (4.10) 
 
Table 4.5   Literature Values of Solute Descriptors 
 
Solute 
Solute Descriptors   
Ref. E S A B V 
5-Fluorouracil 0.72 0.84 0.57 1.02 0.7693 [38] 
Acetaminophen 1.06 1.63 1.04 0.86 1.1724 [73] 
Vanillin 0.99 1.30 0.31 0.68 1.1313 [33] 
Phenol 0.805 0.89 0.6 0.3 0.7751 [73] 
4-Nitrophenol 1.07 1.72 0.82 0.26 0.9493 [73] 
Ethyl Paraben 0.91 1.44 0.73 0.45 1.2722 [74] 
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Figure 4.4   Log(K)fit as a function of log(K)exp using all interaction parameters for 
calculation. 
 
Table 4.6   Calculated Solvent Descriptor using all Interaction Parameters 
  Solvent Descriptors 
Solvent e s a b v c 
(GVGVP)40 + PBS 0.471 -0.572 0.276 -0.919 1.646 -0.336 
(V3(VH)3)4 + PBS 0.169 -0.271 0.141 -0.718 1.203 -0.085 
(LQQ)12 + PBS 1.625 -1.054 0.047 -0.766 1.107 -0.348 
(GVGVP)40 -0.663 0.400 -0.211 -0.757 1.003 0.333 
(V3(VH)3)4 -1.351 1.106 -0.608 -0.323 0.234 0.612 
 
As expected, since the number of adjustable parameters was equal to the number 
of solutes, using all interaction descriptors resulted in perfect agreement between the 
calculated fit and experimental log(K) values (Figure 4.4, Table 4.6).  For a more 
accurate solvent descriptor calculation it has been suggested to solve the system of 
equations in an over-determined condition by using a larger number of solutes than the 
number of adjustable parameters. [41]  Therefore, a series of calculations were performed 
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eliminated one interaction descriptor at a time and recording the value of the objective 
function (Table 4.7). 
 
Table 4.7   Objective Function Value when Interaction Descriptor was Eliminated from 
Linear Free Energy Equation 
  Eliminated Interaction Descriptor 
Solvent eE sS aA bB vV 
(GVGVP)40 + PBS 1.43E-03 1.08E-02 1.02E-02 3.31E-01 2.53E-01 
(V3(VH)3)4 + PBS 2.39E-04 2.57E-03 2.69E-03 1.99E-01 1.32E-01 
(LQQ)12 + PBS 2.22E-02 3.87E-02 2.98E-04 2.27E-01 1.12E-01 
(GVGVP)40 3.69E-03 5.59E-03 5.97E-03 2.21E-01 9.16E-02 
(V3(VH)3)4 1.54E-02 4.26E-02 4.96E-02 4.02E-02 4.99E-03 
 Smallest values for each solvent system shown in yellow, largest in green. 
 
The results of this procedure show that for the four protein systems, (GVGVP)40, 
(GVGVP)40 + PBS, (V3(VH)3)4 + PBS, and (LQQ)12 + PBS, the’ bB’ and ‘vV’ 
interaction descriptors are the most influential of all interaction types.  This indicates that 
solute basicity and its interaction with solvent acidity, along with the solute size and 
solvent dispersive interaction strength are important interactions in these systems.  For 
the (V3(VH)3)4 system the most important interactions arise from those between solute 
acidity and solvent basicity ‘aA’ along with solvent polarizability and dipolar interactions 
‘sS’. 
For all the protein systems the results in Table 4.7 show that no single interaction 
descriptor had the least impact on the objective function.  To compare solvent systems 
with and without the addition of PBS it is necessary to compare systems with the same 
interaction descriptors.  Since the ‘eE’ interaction descriptor had the least impact on the 
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objective function for the most solvent systems ((GVGVP)40 + PBS, (V3(VH)3)4 + PBS, 
and GVGVP)40) and the second least impact for the two remaining systems ((V3(VH)3)4 
and (LQQ)12 + PBS) this interaction descriptor was excluded.  While this excluded 
descriptor had little effect on the objective function for the solute/solvent combinations 
investigated, it is probable that it will become more important as different types of solutes 
and solvents are investigated, but for these solute/solvent combinations, this interaction 
descriptor was eliminated to provide an over-determined condition and then the solvent 
descriptors were recalculated (Figure 4.5, Table 4.8). 
Equation (4.11) shows the LFER equation format for the (GVGVP)40 + PBS 
protein system and describes the respective solvent system where N is the number of 
solutes during data fitting, R2 is the adjusted correlation coefficient, SE is the standard 
error in the dependent variable, and F is the fisher statistic. 
 
 
Figure 4.5   Log(K)fit as a function of log(K)exp for selected interaction parameters. 
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Table 4.8   Calculated Solvent Descriptors using Selected Interaction Parameters 
  Solvent Descriptors 
Solvent s a b v c 
(GVGVP)40 + PBS -0.363 0.219 -0.912 1.608 -0.099 
(V3(VH)3)4 + PBS -0.196 0.121 -0.715 1.189 0.000 
(LQQ)12 + PBS -0.333 -0.150 -0.741 0.976 0.469 
(GVGVP)40 0.106 -0.130 -0.767 1.056 0.000 
(V3(VH)3)4 0.506 -0.444 -0.344 0.343 -0.067 
 
 log(Kco/sn
(GVGVP)40+PBS) = −0.363S + 0.219A − 0.912B + 1.608V − 0.099  (4.11) 
(N = 6; R2 = 0.986; SE = 0.043; F = 90) 
 
The coefficients in Eq. (4.11) are related to the difference in that specific interaction 
property between the coacervate and supernatant phases.  Thus, for the (GVGVP)40 + 
PBS system the coacervate phase is less dipolar/polarizable than the supernatant phase, 
indicated by a negative value for the s-coefficient.  Also, the coacervate phase is a 
stronger hydrogen-bond base (positive a-coefficient), but a weaker hydrogen-bond acid 
(negative b-coefficient).  The positive v-coefficient indicates the coacervate phase is able 
to interact with solutes by dispersive interactions and/or the energy required to create a 
cavity in the coacervate phase is less than that in the supernatant phase.  Equations (4.12) 
through (4.15) represent the remaining solvent systems. 
 
 log(Kco/sn
(V3(VH)3)4+PBS) = −0.196S + 0.121A − 0.715B + 1.189V + 0.000  (4.12) 
(N = 6; R2 = 0.997; SE = 0.015; F = 450) 
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 log (Kco/sn
(LQQ)12+PBS) = −0.333S − 0.150A − 0.741B + 0.976V + 0.469  (4.13) 
(N = 6; R2 = 0.668; SE = 0.149; F = 4) 
 
 log(Kco/sn
(GVGVP)40) = 0.106S − 0.130A − 0.767B + 1.056V + 0.000  (4.14) 
(N = 6; R2 = 0.969; SE = 0.061; F = 41) 
 
 log(Kco/sn
(V3(VH)3)4) = 0.506S − 0.444A − 0.344B + 0.343V − 0.067  (4.15) 
(N = 6; R2 = 0.771; SE = 0.124; F = 5) 
 
 For most of the solutes investigated in this study the partition coefficient 
increased when the experiment was conducted in the presence of PBS (Table 4.4).  In the 
solvent systems investigated the supernatant phase is predominantly water while the 
coacervate phase contains 40-50% protein by mass.  Since the supernatant phase is 
predominantly water and likely to be more polar than the coacervate phase, it can be 
assumed that the dielectric constant of the supernatant phase is greater than that of the 
coacervate phase. [75]  Therefore, during the partitioning process most of the PBS will 
partition into the supernatant phase.  This increase in PBS within the supernatant phase 
results in an increase in the phase’s cohesive energy density.  Solvents of greater 
cohesive energy density require more energy to separate the solvent molecules and create 
a cavity of suitable size during solute transfer between phases.  Using the data from the 
LFER analysis, the cavity formation descriptor (v-descriptor) is shown to decrease with 
 66 
 
the addition of PBS (Table 4.8).  This data is in agreement with the increase in cohesive 
energy density as a result of the addition of PBS and this increase in cavity formation 
energy causes lower solute partitioning into the supernatant phase. 
 For the two solutes investigated, vanillin and 4-nitrophenol, whose partition 
coefficient did not increase with the addition of PBS, their behavior can be explained 
from their pKa values.  The pKa values for these solutes, 7.4 and 7.15 respectively, are 
close to the solute systems partitioning pH values.  When these solutes partition in the 
systems without PBS a larger fraction remains in an uncharged state since the solution pH 
is below their pKa values.  These materials in their uncharged state are more nonpolar 
and will prefer the coacervate phase over the more polar supernatant phase.  When these 
solutes are introduced into the solvent systems with PBS a larger fraction of solute 
becomes ionized and therefore, becomes more soluble within the supernatant phase 
reducing the partition coefficient. 
Combining the experimental data of measured partition coefficients with the 
LFER analysis shows that for greater compound encapsulation and potentially longer 
release rate the ELP tails, or ELP micelle core, should be preferably of greater 
hydrophobicity.  While the critical transition temperature of (V3(VH)3)4 + PBS would 
indicate it is the most hydrophobic of all constructs examined, the solute partition 
coefficients in this system are lower than the (GVGVP)40 + PBS system, especially 
examining the most hydrophobic or least water soluble compound, ethyl paraben.  This 
result would indicate that under physiological conditions (PBS pH 7.4) the coacervate 
produced from the (GVGVP)40 system is more hydrophobic than the (V3(VH)3)4 system 
and therefore, the same conclusion for the micelle interior.  If a relationship exists 
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between the ELP transition temperature, hydrophobicity, and solute partitioning, it would 
be difficult to design an ELP structure that provides high encapsulation within the micelle 
interior based only on using transition temperature as a measure of hydrophobicity.  
According to the LFER analysis, the dominate interaction under physiological conditions 
is the dispersive energy and cavity formation term.  Dispersive interactions are dominate 
in non-polar hydrocarbon chains and influence solute retention time on reverse phase C18 
HPLC columns. 
 
 
Figure 4.6   Chromatogram showing (LQQ)12, (V3(VH)3)4, and (GVGVP)40 ELP.  Mobile 
phase A composition was 5% (v/v) acetonitrile in PBS.  Mobile phase B composition was 
100% acetonitrile.  Gradient elution 0 to 50% B over 30 minutes. 
 
According to HPLC retention time on a C18 stationary phase column using PBS 
(0.15 M NaCl, 0.01 M Na3PO4, pH 7.4) as the mobile phase, the gradient elution pattern 
suggests the (GVGVP)40 construct is of greater dispersive interaction energy than the 
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(V3(VH)3)4 construct, which is in agreement with the partitioning and LFER data (Figure 
4.6).  Therefore, during the design of future ELP constructs for their use in drug 
encapsulation and delivery, it is suggested to use ELP transition temperatures as only an 
approximation  of hydrophobicity, and this data should be combined with HPLC relative 
retention times to measure ELP dispersive interaction energy as a better indicator of 
solute partitioning behavior. 
 
Doxorubicin Partitioning and LFER Analysis 
Doxorubicin is an anthracycline chemotherapeutic commonly used to treat many different 
forms of cancer (Figure 4.7).  Unfortunately, the clinical use of anthracyclines is limited 
by dose related cardiomyopathy and becomes more prevalent during treatment due to the 
cumulative effect of the drug. [76]  Since myocardial injury is known to occur 
cumulatively, starting from the first dose of treatment, there has been much effort in the 
development a drug delivery system or formulation that reduces this damaging side 
effect. [76, 77, 78]  In an attempt to decrease its cumulative cardiotoxicity and increase 
its therapeutic efficiency, several authors have investigated doxorubicin’s ability to be 
encapsulated or conjugated within micelles and liposomes. [76, 79, 80, 81, 82, 83] 
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Figure 4.7   Molecular structure of doxorubicin 
 
Supplied as its hydrochloride salt, doxorubicin has good water solubility (29 mg/mL) and 
with a high molar absorption coefficient it is easy to detect by UV-VIS spectroscopy at 
low concentrations.  To investigate the potential of an ELP drug delivery platform to 
encapsulate doxorubicin this solute was partitioned, under physiological conditions, in 
the most hydrophobic solvent system investigated in this study, (GVGVP)40 + PBS.  
Abraham descriptors for doxorubicin were obtained from the Open Abraham Descriptor 
Data Explorer (Table 4.9). [84]  The measured partition coefficient and 95% confidence 
interval for doxorubicin was 150 and 44 respectively (Figure 4.8).   
 
Table 4.9   Solute Descriptors for Doxorubicin Obtained from Open Abraham Descriptor 
Database 
 
 
 
 
 
Solute 
 Solute Descriptors 
E S A B V 
5-Fluorouracil 0.72 0.84 0.57 1.02 0.7693 
Acetaminophen 1.06 1.63 1.04 0.86 1.1724 
Vanillin 0.99 1.30 0.31 0.68 1.1313 
Phenol 0.805 0.89 0.6 0.3 0.7751 
4-Nitrophenol 1.07 1.72 0.82 0.26 0.9493 
Ethyl Paraben 0.91 1.44 0.73 0.45 1.2722 
Doxorubicin 3.63 4.1 1.3 3.41 3.728 
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Figure 4.8   Partitioning data for doxorubicin in the (GVGVP)40 + PBS solvent system. 
 
 
Table 4.10   Solvent Descriptors for Solvent System (GVGVP)40 + PBS Obtained from 
Linear Regression of Solute Set with and without Including Doxorubicin 
Solvent 
Solvent Descriptors 
e s a b v c 
(GVGVP)40 + PBS 0.471 -0.572 0.276 -0.919 1.646 -0.336 
(GVGVP)40 + PBS with Dox. 0.363 -0.526 0.264 -0.921 1.632 -0.273 
 
 
Figure 4.9   Log(K)fit as a function of log(K)exp for the (GVGVP)40 + PBS solvent system 
with doxorubicin included in the solute set. 
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With the addition of doxorubicin to the solute set, the larger number of solutes 
allows the inclusion of the ‘eE’ interaction descriptor while still providing an over-
determined condition during regression analysis (Table 4.10, Figure 4.9).  As shown in 
Table 4.10 the inclusion of doxorubicin into the solute set has changed the solvent 
descriptors.  Using the original solvent descriptors, where the solute system did not 
include doxorubicin to calculate the partition coefficient of doxorubicin, resulted in an 
overestimation of its partition coefficient, but as expected all other solutes fit the model 
perfectly (Table 4.11).  A possible explanation for this result is the large difference in the 
solute descriptors for doxorubicin compared to all other solutes investigated (Table 4.9).  
When the partition coefficients were calculated using the LFER model that includes 
doxorubicin in the solute set, Eq. (4.16), it is shown that this model can accurately 
predicts the partition coefficient of doxorubicin.  Also, this model shows reasonable 
agreement between the calculated fit and experimental partition coefficients for all 
remaining solutes within the set (Table 4.11).  
 
Table 4.11   Calculated Solute Partition Coefficients using Solvent Descriptors from Table 
4.10 and Solute Descriptors from Table 4.9 
  
Kfit 
Solute Kexp 
With 
doxorubicin. 
Without 
doxorubicin 
5-Fluorouracil 1.02 1.03 1.02 
Acetaminophen 4.54 4.47 4.54 
Vanillin 5.12 5.07 5.12 
Phenol 5.01 4.99 5.01 
4-Nitrophenol 5.42 5.46 5.42 
Ethyl Paraben 14.2 14.3 14.2 
Doxorubicin 150 150 245 
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log(Kco/sn
(GVGVP)40+PBS) = 0.363E − 0.526S + 0.264A − 0.921B + 1.632V − 0.273  (4.16) 
(N = 7; R2 = 1.00; SE = 0.086; F = 4,707) 
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CHAPTER V 
CONCLUSION 
 
To provide insight into the potential use of elastin-like polypeptides as a drug 
delivery platform solute partitioning was performed using three ELP constructs with 
varying hydrophobicity.  Protein solutions were prepared with and without the addition of 
PBS to investigate the influence of PBS on solute partitioning.  All partitioning data was 
subject to a LFER analysis to characterize the two phases that resulted from the 
partitioning process.  Due to the clinical importance of doxorubicin, it was partitioned 
into the most hydrophobic system investigated, (GVGVP)40 + PBS, in an effort to 
maximize its encapsulation efficiency.  Finally, doxorubicin was added to the solvent set 
and the LFER coefficients for the (GVGVP)40 + PBS solvent system were recalculated. 
The LFER results indicate of all 5 interaction descriptors the two most dominate 
were the dispersive interaction and cavity formation term followed by the solvents 
hydrogen bond acidity.  For the solutes investigated, greater partitioning into the 
coacervate phase was observed in ELP systems that were determined to have a stronger 
dependence on dispersive interactions and solute size.  After the addition of doxorubicin 
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to the solute set and recalculation of the (GVGVP)40 + PBS solvent system’s LFER 
coefficients, reasonable agreement between the calculated fit and experimental partition 
coefficients was observed. 
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APPENDIX 
Appendix A 
 
Lysogeny Broth (LB) Media Preparation 
1. To prevent boil-over during autoclaving the media vessel should only be filled to 
a maximum of 75% volume.  The appropriate media vessel was charged with 5 
g/L media yeast extract, 10 g/L media peptone, 5 g/L media sodium chloride then 
filled to the final volume using deionized water. 
2.  Media sterilization was performed using a steam autoclave (Cycle: 121oC for 45 
min). 
3. Once media was cooled to room temperature ampicillin was added at a 
concentration of 100 mg/L media. 
 
Protein Expression 
One Liter Expression Scale 
1. For each liter of expression media, starter cultures were grown from a frozen 
glycerol bacterial stock culture by inoculating two 15 mL sterile culture tubes 
filled with 10 mL of previously prepared LB media with ampicillin. 
2. The inoculated media was grown at 37oC overnight (approximately 16 hours) on a 
shaker table (250 rpm). 
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3. The following day both starter cultures were added to a 2 L Erlenmeyer flask 
charged with 1 L LB media with ampicillin at 37oC. 
4. This culture was grown at 37oC on a shaker table (250 rpm) while monitoring the 
growth rate using a UV-VIS spectrometer. 
5. Growth was allowed to continue until the optical density measured at 600 nm 
(OD600) was between 0.8 and 1.2 absorbance units (4-8 hours). 
6. Once the optical density reached the target range the culture was induced using 
200-240 mg/L media isopropyl β-D-1-thiogalactopyranoside (IPTG). 
7. Induction was allowed to proceed for a minimum of 5 hours then bacteria were 
isolated by centrifugation (20oC, 10,000xg, 10 min). 
8. When necessary the isolated pellet was stored overnight at -20oC. 
 
Six Liter Expression Scale 
1. Starter cultures were grown from a frozen glycerol bacterial stock culture by 
inoculating two 15 mL sterile culture tubes filled with 10 mL of previously 
prepared LB media with ampicillin. 
2. The starter cultures were grown for 4 hours at 37oC on a shaker table (250 rpm) 
then transferred to a 2 L Erlenmeyer flask containing 1 liter of previously 
prepared LB media with ampicillin. 
3. This 1 liter starter culture was grown overnight (approximately 16 hours) at 25oC 
on a shaker table (200 rpm). 
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4. The following day, the bacteria from the 1 liter starter culture was isolated by 
centrifugation (20oC, 10,000xg, 10 min) and re-suspended by gently swirling in 
250 mLs sterilized deionized water or previously prepared LB media. 
5. Once re-suspended the pellet suspension was transferred to the final expression 
vessel. 
The final expression vessel consisted of an 8 liter wide mouth 
polypropylene mason jar (Bel-Art #109170000) filled to 6 liters LB media with 
ampicillin.  This media was prepared and steam autoclaved (Cycle: 121oC for 90 
min) in the expression vessel the previous day then allowed to equilibrate to 37oC 
overnight in a temperature controlled water bath. 
6. Using a steam autoclaved air stone (autoclaved with the final expression vessel 
and media) media oxygenation and agitation was performed by bubbling sterile 
filtered air into the media at a rate of approximately 1 liter per hour.  Occasionally 
it was necessary to reduce the air flow rate due to excessive foaming of the media. 
Note:  While this combined agitation and oxygenation method was successful, 
reducing the air flow rate to prevent excess foaming resulted in increasing the 
time necessary to reach the required OD600 range.  If this increase in time to reach 
the required OD600 range is due to the reduced agitation at the lower air flow rate 
then a better method would be to separate the agitation and oxygenation 
techniques.  By stirring the media using an external stirring source while 
providing oxygenation at an air flow rate that prevents excessive media foaming 
growth rate may be increased reducing the time to reach the required OD600 range.    
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7. After inoculation of the 6 L culture, growth was monitored by UV-VIS 
spectroscopy. 
8. Once an OD600 of 0.8 to 1.2 was obtained (4-8 hours) the culture was induced 
using IPTG (200-240 mg/L media). 
9. Induction was allowed to proceed for a minimum of 5 hours then bacteria were 
isolated by centrifugation (20oC, 10,000xg, 10 min). 
10. When necessary the isolated pellet was stored overnight at -20oC. 
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Appendix B 
 
Protein Extraction Protocol 
1. For both the 1 liter and 6 liter expression volumes protein extraction from the 
bacterial pellet was performed by lysing the bacterial cells followed by cold 
centrifugation.  Cell lysis was performed by combining all bacterial pellets into 30 
mL cold (5-10oC) deionized water per liter of expression culture. 
2. Next, pulse sonication (550 Sonic Dismembrator, Fisher Scientific) was 
performed to disrupt the bacterial wall and allow protein to be extracted.  For the 
1 L expression volume, sonication time was 5 minutes and at the 6 L expression 
scale the sonication time was doubled to 10 minutes.  Sonication pulse sequences 
were identical at both volumes (<10oC, pulse cycle: 10 s on 20 s off, 100% 
power). 
3. After sonication, the cell lysate (Cell Lysate Solution) was cooled in an ice-bath 
below 5oC then cold centrifuged (3oC, 20,000xg, 20 min) to remove insoluble 
cellular material. 
4. Finally, the aqueous protein solution (Crude Protein Solution) was decanted from 
the insoluble material for further purification by inverse transition cycling. 
 
Protein Purification by Inverse Temperature Cycling 
Protein purification was performed by inverse transition cycling (ITC).  Three 
rounds of ITC were performed using deionized water for all pellet re-suspensions.  Re-
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suspension volumes for each round of purification were 15, 5, and 1 mL/L culture 
respectively.  Pellet re-suspensions were performed using pulse sonication (<10oC, pulse 
cycle: 10 s on 20 s off, 100% power) when necessary. 
Inverse Transition Cycling Protocol for Construct (GVGVP)40 
1. For construct (GVGVP)40, the ITC protocol began by quickly heating the crude 
protein solution obtained after cold centrifugation to 55oC using a 70oC hot water 
bath. 
2. Once heated to temperature the protein solution was allowed to sit in an incubator 
for 30 minutes at 55oC.  During this time the ELP and additional impurities 
separated from solution. 
3. After this incubation period, the aggregated ELP and supernatant phases were 
separated by hot centrifugation (40oC, 20,000xg, 10 min) followed by decanting 
of the supernatant phase. 
4. Next, the pellet containing ELP was re-suspended in 15 mL/L culture deionized 
water with cooling and slight mixing. 
5. Once re-suspended, the protein solution was centrifuged cold (3oC, 20,000xg, 10 
min) to remove insoluble impurities. 
6. This completes one round of ITC, two additional rounds were performed using re-
suspension volumes of 5 and 1 mL/L culture respectively. 
7. After all rounds of ITC were complete the protein solution was filtered through a 
0.22 µm syringe filter and stored at 4oC or lyophilized until needed. 
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Inverse Transition Cycling Protocol for Construct (LQQ)12 
The ITC protocol for construct (LQQ)12 was identical to that of (GVGVP)40 with 
the exception that sodium chloride was added to all hot cycles (2 M NaCl final 
concentration).  Pellet re-suspensions were performed using pulse sonication (<10oC, 
pulse cycle: 10 s on 20 s off, 100% power) when necessary. 
1. For construct (LQQ)12, the ITC protocol began by adding solid sodium chloride to 
the crude protein solution obtained after cold centrifugation to a final 
concentration of 2 M NaCl. 
2. Next, this solution was quickly heated to 55oC using a 70oC hot water bath. 
3. Once heated to temperature the protein solution was allowed to sit in an incubator 
for 30 minutes at 55oC.  During this time the ELP and additional impurities 
separated from solution. 
4. After this incubation period, the aggregated ELP and supernatant phases were 
separated by hot centrifugation (40oC, 20,000xg, 10 min) followed by decanting 
of the supernatant phase. 
5. Next, the ELP phase was re-suspended in 15 mL/L culture deionized water with 
cooling and slight mixing. 
6. Once re-suspended, the protein solution was centrifuged cold (3oC, 20,000xg, 10 
min) to remove insoluble impurities. 
7. This completes one round of ITC, two additional rounds were performed using re-
suspension volumes of 5 and 1 mL/L culture respectively.  Solid sodium chloride 
was added to all hot cycles. 
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8. After all rounds of ITC were complete the protein solution was filtered through a 
0.22 µm syringe filter and stored at 4oC or lyophilized until needed. 
 
Inverse Transition Cycling Protocol for Construct (V3(VH)3)4 
Since the protein construct (V3(VH)3)4 has the ability to accept a charge, the protein 
purification procedures included a solution pH change to increase or decrease the 
solutions transition temperature. 
1. The purification procedure began with the cell lysate solution after sonication.  At 
this stage, the pH of the protein solution was adjusted between 3 and 4 using 1 M 
HCl.  During the addition of acid additional impurities were precipitated from 
solution while the protein construct remained in solution. 
2. Next, the acidic protein solution was cooled in an ice-bath below 5oC and cold 
centrifuged (3oC, 20,000xg, 20 min) to remove insoluble cellular material. 
3. After cold centrifugation the acidic aqueous protein solution was decanted from 
the insoluble material then the pH of the supernatant adjusted between 7 and 8 
using 1 M NaOH.  Also, solid sodium chloride was added to provide a final 
solution concentration of 2 M NaCl. 
4. This solution was quickly heated to 55oC using a 70oC hot water bath. 
5. Once heated to temperature the protein solution was allowed to sit in an incubator 
for 30 minutes at 55oC.  During this time the ELP and additional impurities 
separated from solution. 
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6. After this incubation period, the aggregated ELP and supernatant phases were 
separated by hot centrifugation (40oC, 20,000xg, 10 min) followed by decanting 
of the supernatant phase. 
Note:  Due to the addition of acid additional impurities were removed in the first 
stage of purification.  This left a smaller pellet size at this stage compared to that 
obtained from purifications of other constructs without the addition of acid.  Also, 
the appearance of the pellet looks more viscous or “coacervate-like” and does not 
contain the addition of particulate matter commonly observed in other 
purifications at this stage.  It may be beneficial to investigate this purification 
method on other ELP constructs. 
7. Because of the coacervate appearance and size the re-suspension volume was 
reduced to 5 mL/L culture deionized water. 
8. Once re-suspended, the protein solution was centrifuged cold (3oC, 20,000xg, 10 
min) to remove insoluble impurities. 
9. After centrifugation the soluble fraction was decanted. 
10. This solution was quickly heated to 55oC using a 70oC hot water bath. 
11. Once heated to temperature the protein solution was allowed to sit in an incubator 
for 30 minutes at 55oC.  During this time the ELP and any remaining impurities 
separated from solution. 
12. After this incubation period, the aggregated ELP and supernatant phases were 
separated by hot centrifugation (40oC, 20,000xg, 10 min) followed by decanting 
of the supernatant phase. 
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13. The aggregated ELP was re-suspended in 1 mL/L culture, cooled in an ice-bath 
and filtered through a 0.22 µm syringe filter. 
14. After filtration the solution was stored at 4oC or lyophilized until needed. 
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Appendix C 
 
Solute linearity check at 280 nm wavelength. 
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